In the quest to transform cancer treatment, immunotherapy has ushered in a new era of hope – reshaping patient outcomes and inspiring fresh possibilities for families and clinicians alike.
The next wave of immunotherapies has been advancing rapidly, broadening the reach of innovative treatments like chimeric antigen receptor (CAR)-T cell therapies – including brexucabtagene autoleucel and tisagenlecleucel for leukemia. This progress is powered by analytical technologies that bring precision and clarity to development and manufacturing.
One of the most exciting frontiers in this space is immunopeptidomics – the comprehensive analysis of antigenic peptides displayed by major histocompatibility complex (MHC) molecules using advanced liquid chromatography-tandem mass spectrometry (LC-MS/MS). This emerging discipline is unlocking insights into how tumors present antigens and interact with the immune system, laying the groundwork for the next generation of immunotherapies, including highly targeted CAR-T cell treatments and personalized cancer vaccines.
Immunopeptidomics enables detailed profiling of antigenic peptides presented on the surface of tumor and antigen-presenting cells. This approach is particularly valuable for studying hard-to-treat cancers such as pancreatic ductal adenocarcinoma (PDAC), a malignancy often diagnosed at later stages, where conventional treatments offer limited success. PDAC’s immunosuppressive tumor microenvironment poses significant challenges for CAR T therapies. However, immunopeptidomics is helping researchers identify novel T-cell targets and tumor-specific antigens (TSAs), including spliced peptides, post-translationally modified (PTM) peptides, and cryptic peptides, which can inform the design of more effective therapies.
Analytical challenges in immunopeptidomics
While immunopeptidomics offers great possibilities, it also presents unique analytical challenges, particularly when compared to traditional proteomics. Conventional proteomics relies on digesting proteins into peptides for identification using protein databases. To tackle these obstacles, researchers employ specialized workflows involving immunoaffinity purification, high-resolution LC-MS/MS, and advanced, AI-driven bioinformatics tools. These techniques enhance the ability to detect and characterize the vast diversity of HLA-bound peptides, including those with PTMs or sequence isomers, which are critical for understanding immune responses.
High-resolution mass spectrometry (HRMS) has become the backbone of immunopeptidomics, enabling the identification of peptides bound to MHC molecules. The latest innovations in MS technology, such as information-dependent acquisition (IDA), also known as data-dependent acquisition (DDA), and data-independent acquisition (DIA), are essential for achieving comprehensive immunopeptidome coverage.
IDA/DDA provides high-confidence fragmentation spectra for selected precursors, ensuring precise peptide identification. DIA, on the other hand, offers broader proteomic coverage and improved reproducibility across replicates, making it ideal for large-scale studies.
One important development in MS technology is tunable electron-activated dissociation (EAD), which enhances peptide fragmentation by selectively breaking peptide backbones while preserving labile modifications or resolving isomeric residues. For instance, EAD enables researchers to differentiate between isobaric amino acids such as leucine and isoleucine, which possess the same molecular mass but exhibit distinct structural and biological properties. This differentiation is vital because leucine and isoleucine can influence the shape, binding specificity, and overall function of peptides within antigen-binding domains, ultimately affecting immune recognition and response.
Similarly, EAD can differentiate between aspartate and isoaspartate, isomeric PTMs formed through deamidation. These modifications can affect peptide stability and antigenicity, providing insights into disease progression or immune evasion mechanisms.
To tackle the diverse challenges of immunopeptidomics, researchers are increasingly combining multiple analytical approaches – improving specificity, reducing background noise, and achieving higher throughput without compromising data quality. For example, EAD is used for resolving structural isomers and PTMs, whereas DIA ensures comprehensive coverage of the immunopeptidome, minimizing missing values and improving reproducibility, while also enabling the generation of permanent digital maps of the proteome, which can be revisited for retrospective analyses. In addition, targeted methods such as multiple reaction monitoring (MRM) can be employed in tandem to validate tumor-specific antigens and quantify functionally relevant peptides.
Applications in immunotherapy development
The insights gained from immunopeptidomics are driving the rational design of novel cancer immunotherapies. By decoding the tumor-immune interface, researchers can identify new immune targets, understand mechanisms of immune escape, and develop therapies tailored to the unique antigenic landscape of each tumor. For example, CAR-T cell therapies can be refined by selecting T-cell targets identified through immunopeptidomics and peptide-based vaccines benefit from the discovery of novel tumor-specific antigens, including those with PTMs or spliced sequences.
Looking ahead, innovations in peptide separation, MS technology, and bioinformatics will continue to drive progress in translational oncology, paving the way for more effective and personalized cancer immunotherapies.
Newsletters
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
